MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2147/dddt.s558221

Медицинская библиотека · Drug design, development and therapy · 2025

Targeting THR-β for MASLD: Mechanisms and Drug Development.

Hua Yunlong, Liu Yang, Xing Lianjun, Yu Xiao, Zheng Peiyong, Yang Lili, Song Haiyan

СтатьяОбзорПеревод пока не подготовлен

Аннотация

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, but there has long been a lack of effective therapeutic drugs. Thyroid hormone (TH) and its receptor THR-β play pivotal roles in hepatic metabolism, positioning THR-β as a promising therapeutic target for MASLD. Notably, Resmetirom, a selective THR-β agonist, gained FDA approval in 2024 for MASLD treatment, and several other THR-β agonists are currently undergoing preclinical or clinical studies. While these agents demonstrate effective in alleviating hepatic steatosis, inflammation, and fibrosis in MASLD, the disease heterogeneity and drugs' adverse reactions remain key challenges. Therefore, further research is necessary to comprehensively assess their clinical efficacy and safety. This review summarizes the mechanisms by which TH/THR-β influences MASLD and recent advances in THR-β-targeted pharmacotherapy, aiming to enhance understanding of its therapeutic potential and promote drug development and clinical applications.

Для цитирования: Hua Yunlong, Liu Yang, Xing Lianjun, Yu Xiao, Zheng Peiyong, Yang Lili, Song Haiyan. Targeting THR-β for MASLD: Mechanisms and Drug Development.. Drug design, development and therapy. 2025. DOI: 10.2147/dddt.s558221.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.